NantHealth Announces Global Expansion Of GPS Cancer; Partners With Sorgente To Expand Availability Of GPS Cancer™ To Italy

NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has entered into an exclusive reseller agreement for  GPS Cancer tests with  Sorgente, the market leader in biobank, stem cell and now molecular profiling testing in Italy. The molecular tests help guide the decisions made by oncologists for a patient's treatment strategy including choice of standard chemotherapy. The launch of this partnership comes on the heels of the kick-off of the  XVIII Congresso Nazionale Aiom, (National Congress of the Italian Association of Medical Oncology), which took place in Rome, October 28-30 th at the Marriott Park Hotel.

"As momentum continues to build not only nationally for GPS Cancer tests, but internationally as well, we're excited to bring Sorgente onboard as our exclusive distributor of the test throughout Italy," said Patrick Soon-Shiong, MD, CEO of NantHealth. "For a country with a population of nearly 60 million people, Italy makes up one of the top 25 countries for cancer diagnosis. In 2016 in Italy alone, 176,200 women were diagnosed with cancer while there were 189,600 new diagnoses for men; this disease is touching the lives of so many worldwide and we're excited at the possibilities GPS Cancer tests offer in terms of personalizing treatment options - something the industry is striving towards. Through this partnership, we're able to offer Italian physicians the ability to make better informed decisions about treatment options for cancer patients - including choices for standard chemotherapy. Oncologists are recognizing that the value of GPS lies not only in providing insight into the responsiveness of the tumor for therapeutic decisions, but perhaps more importantly, providing guidance as to the presence of proteins in the tumor tissue that may indicate resistance to standard chemotherapy and avoiding unnecessary toxicities."

Since the launch of its commercial availability in  June 2016, GPS Cancer now has an established global footprint in the European market, which adds to the growing set of payers, providers, and Fortune 50 companies that have already committed to covering or using the comprehensive profiling test. Under the terms of the agreement, Sorgente will have exclusive rights to distribute GPS Cancer to physicians in Italy. The test, which integrates quantitative proteomics with whole genome (DNA) and transcriptome (RNA) sequencing, is the only integrated comprehensive molecular test of its type conducted in CLIA-certified and CAP-accredited laboratories. It provides oncologists with a comprehensive molecular profile of a patient's cancer to inform personalized treatment strategies. As a cornerstone of the Cancer MoonShot 2020 program, GPS Cancer provides key insights based on the unique biology of a patient's tumor—from the DNA to the RNA to the protein. This rich information helps doctors build more effective treatment plans based on FDA-approved drugs and active clinical trials, while enabling cancer researchers to design new clinical trials that harness the potential of the immune system.

"As Sorgente has traditionally been focused on providing the best services in umbilical cord blood banking and in genetic testing, the opportunity to partner with NantHealth for its GPS Cancer molecular profiling tests is an exciting one as we expand our mission of bringing healthcare providers the best and most advanced tools to treat patients," said Marco Dotto, project manager for the oncology department in Sorgente Genetica. "In 2015, it was recorded that 4.5 percent of the Italian population was diagnosed with a tumor; this makes up a significant portion of our country and by partnering with NantHealth, we're excited to bring physicians best-in-class tests that will help treat issues related to cancer that are not only affecting so many in Italy, but also worldwide."

If you liked this article you might like

Discovery's David Zaslav Shows It's Good to Be a Media CEO

Tronc's Latest Fusillade Targeting Soon-Shiong Gets to Core Question

7 Stocks Making Big Moves With Unusual Volume

'Mad Money' Lightning Round: Take American Electric Power Over Calpine

Jim Cramer's 'Mad Money' Recap: These Stocks Matter More Than Others